What question did this study set out to answer?

To evaluate serum Flt3 ligand kinetics during induction therapy and determine its utility as a noninvasive biomarker of marrow cellularity and clinical prognosis in acute myeloid leukemia.

October 22, 2019Blood AdvancesOpen Access

Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia

View Full Paper

Ask AI

Bookmark

Authors

PMPaul MilneNIHR Newcastle Biomedical Research Centre CWCharlotte S. Wilhelm-BenartziBetsi Cadwaladr University Health Board MGMichael R. GrunwaldLevine Cancer Institute

Discussion

Member takes

Implication

Randomized trial reveals that serum Flt3 ligand levels correlate with remission and survival in acute myeloid leukemia, highlighting its utility as a noninvasive prognostic biomarker.

Key Points

To evaluate serum Flt3 ligand kinetics during induction therapy and determine its utility as a noninvasive biomarker of marrow cellularity and clinical prognosis in acute myeloid leukemia.
Tracked weekly serum Flt3 ligand (Flt3L) levels during the first 6 weeks of induction chemotherapy and monitored serial levels following hematopoietic stem cell transplantation.
Analyzed day 26 serum Flt3L in a randomized trial subgroup of 140 patients with Flt3-mutated acute myeloid leukemia assigned to lestaurtinib or placebo in the UK NCRI AML17 trial.
Attainment of complete remission strongly correlated with elevated day 26 Flt3L concentrations relative to refractory disease (Mann-Whitney U P < .0001).
Day 26 Flt3L levels ≤291 pg/mL were associated with inferior event-free survival, whereas levels >1185 pg/mL conferred significantly higher overall survival (P = .0119).
Prognostic risk stratification improved when combining day 26 Flt3L with minimal residual disease status, with Flt3L maintaining near-significant survival association after multivariable adjustment.

Cite This Study

Milne et al. (2019) studied this question.

synapsesocial.com/papers/6a75ef7ed01cd5d9a17070c0 https://doi.org/10.1182/bloodadvances.2019000197

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial reveals that serum Flt3 ligand levels correlate with remission and survival in acute myeloid leukemia, highlighting its utility as a noninvasive prognostic biomarker.

Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider